Epitalon Compounding Legal Status: What Patients and Providers Need to Know

What the current status is

Epitalon, also called epithalon, is a synthetic tetrapeptide distinct from epithalamin, an animal pineal-gland extract [1]. Its sequence is Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, and FDA treats the two as separate substances, so studies of epithalamin are not studies of epitalon [1]. FDA says epitalon first appears to have been synthesized in 1999 [1].

For compounding, federal law gives state-licensed pharmacies and physicians three routes to a bulk substance: it complies with a United States Pharmacopeia or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on FDA's list of bulk drug substances that can be used in compounding [4]. Epitalon takes none of them. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy or authorized by the European Medicines Agency [1].

What FDA's lists and interim policy actually say

FDA's interim policy sorts nominated bulk substances into three categories. For category 1 substances, FDA says it does not intend to take action against a compounder using them, provided the conditions in its guidance are met [4]. Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, and it is not on FDA's separate list for outsourcing facilities, updated March 21, 2025, so the category 1 policy does not reach it [2][3][4]. FDA also found no pharmacy that compounds epitalon and no outsourcing facility reporting it [1].

The one FDA page that does list epitalon

FDA's page on bulk substances that may present significant safety risks is where epitalon shows up. It sits in the nominated but withdrawn table, which holds substances previously in category 2 of the interim policies whose nominators withdrew them [8]. FDA's stated concerns are that it has not identified safety-related information regarding epitalon for the proposed route of administration, so it lacks enough information to know whether the drug would cause harm, and that injectable peptides may pose immunogenicity risk from aggregation and peptide-related impurities [8]. Removal from category 2 was not a finding that epitalon is safe [8].

What happened at the July 2026 advisory committee

FDA's Pharmacy Compounding Advisory Committee reviewed epitalon free base and epitalon acetate for the nominated use of insomnia on July 24, 2026 [5]. The committee voted in favor of adding epitalon to the pharmacy bulks list, against FDA staff's recommendation [1][5]. Epitalon is not on the list now; adding it takes formal rulemaking [5].

FDA staff had proposed, in the July 2026 briefing document, that neither epitalon free base nor epitalon acetate be added [1]. Staff evaluated only the insomnia use; the other nominated uses, such as anti-aging and telomere lengthening, were not evaluated for lack of information. The reasons given were that epitalon is not well characterized, has limited historical use, has no evidence of effectiveness for insomnia and no clinical safety data, carries an immunogenicity concern for subcutaneous injection, and that many FDA-approved insomnia drugs exist [1]. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

Does the HHS draft policy make epitalon legal to compound?

No. HHS filed a draft enforcement-discretion policy on October 28, 2026, as Federal Register document 2026-22192, with publication scheduled for October 30, 2026 and comments due two weeks after publication [6]. It names epitalon among six peptides, alongside BPC-157, KPV, MOTS-c, Semax and TB-500 [6]. It covers epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses [7]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with it when the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label stating that the product is a compounded drug product and not for resale [6][7].

The notice states that the policy does not establish any rights for any person and is not binding on HHS or the public, and that HHS may revisit it, for example if a safety signal or a product quality issue arises [6]. It does not put epitalon on any bulk substances list. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they reach patients [6].

Has epitalon been approved or designated anywhere?

Epitalon is not an FDA-approved drug. FDA's review found no approved product in the countries it checked, none authorized by the European Medicines Agency, and no pharmacopeial monograph [1]. It did receive an FDA orphan drug designation for retinitis pigmentosa on September 2, 2010, which was withdrawn on January 6, 2016 [1]. A 2015 published analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [1][9].

Why FDA staff recommended against listing it

FDA found three human studies of epitalon: two involving sublingual use in night-shift workers and one involving an injection beside the eye for retinitis pigmentosa [1]. It found no study of epitalon in people with insomnia, and no clinical study that assessed epitalon's safety [1]. A 2026 narrative review reached a similar place: human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, no adequately powered randomized trial has established efficacy, pharmacokinetic and long-term safety data remain inadequate, and epitalon is described as biologically active but clinically unproven [10].

The telomere claim often made for epitalon also bears on safety. In cultured human fetal fibroblasts that lack telomerase, epitalon induced the catalytic subunit of telomerase, telomerase activity and telomere elongation. That is a cell-culture result, not a human trial [11]. FDA noted that longer telomeres are generally linked to higher cancer risk and warned that telomerase activation gives epitalon a mechanistic potential to be carcinogenic. Its mouse studies of cancer and chromosome damage used one fixed dose in female mice over short exposure, which was too limited to show safety [1].

What is being sold, and what the dosing claims rest on

Epitalon is sold online as research-use-only vials of 10 mg to 50 mg, as capsules and as oral sprays, promoted as an anti-aging peptide that lengthens telomeres [1]. There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, with one site suggesting a course every four months; that is marketing, not evidence [1]. One sublingual study used a spray delivering about 0.5 mg per day for 20 days; another human study used an injection beside the eye [1].

FDA found no pharmacokinetic data for epitalon [1]. FDA searched its adverse event database through December 8, 2025 and its food and supplement complaint system through December 5, 2025 and retrieved no epitalon reports [1].

Is epitalon prohibited in sport?

Epitalon is not named on WADA's 2026 Prohibited List or on the tracked-changes version of the 2027 list dated August 26, 2026 [12][13]. Class S0 prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and the list gives BPC-157 only as an example, introduced by the words including but not limited to [12]. The lists do not say whether epitalon falls under S0, so neither a ban nor an allowance can be stated [12][13].

What this means for a prescription

A prescription for compounded epitalon asks a pharmacy to prepare a substance that is on neither federal bulks list and that sits in the nominated but withdrawn table of FDA's safety-risk page [2][3][8]. The HHS draft names epitalon and describes conditional enforcement discretion [6][7]. The clinical picture is unchanged: three small human studies, no pharmacokinetic data and no approved dose [1][10].